Head & Neck Cancer

Use of unilateral intensity-modulated radiotherapy reduced acute toxicities and maintained oncologic outcomes compared with bilateral IMRT in patients with lateralized palatine tonsillar cancer, according to the results of a new study.

FDG-PET/CT surveillance using a standardized reporting criteria 12 weeks after concurrent chemoradiotherapy was reliable in patients with locoregionally advanced head and neck squamous cell carcinoma, except in patients with late manifesting residual disease, according to the results of the ECLYPS study.

This video highlights studies on HPV-positive head and neck cancer presented at the 2017 ASTRO Annual Meeting.

Chemoprevention with low-dose 13-Cis retinoic acid, a synthetic vitamin A derivative, did not lower the incidence of second primary tumors in patients with squamous cell cancer of the head and neck.

The addition of high-intensity primary tumor ablation in addition to systemic chemotherapy may improve the survival of patients with metastatic head and neck squamous cell carcinoma.

Adherence to each of five quality metrics for head and neck squamous cell carcinoma was associated with a reduced risk for death.

Higher nodal yield during definitive surgery for clinically node-negative oral cavity squamous cell carcinoma was associated with improved mortality.

Three-weekly cisplatin is superior to a weekly dose in preventing locoregional relapse when combined with radiotherapy in head and neck squamous cell carcinoma.

Patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with the checkpoint inhibitor nivolumab were able to maintain baseline levels of quality of life.

The addition of two cycles of neoadjuvant chemotherapy to concurrent chemoradiotherapy improved tumor control in patients with nasopharyngeal carcinoma.

This video reviews results of LUX-Head & Neck 2, a randomized phase III trial that studied afatinib as adjuvant therapy in patients with unresected squamous cell head and neck cancer.

This video highlights results of a phase III randomized trial that tested chemotherapy plus bevacizumab in patients with recurrent or metastatic head and neck cancer.

Prophylactic HPV vaccination significantly reduced vaccine-type oral HPV infections among young adults, according to the results of a cross-sectional study.

Improving oropharyngeal cancer survival rates necessitates better coordination of survivorship care between oncology teams and primary care providers, according to a presentation at ONS.

A new study is suggesting there may be an association with high tumor levels of the protein PD-L1 and head and neck disease recurrence.

Surgery followed by postoperative radiotherapy was associated with prolonged overall survival compared with concurrent chemoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma.

Oropharyngeal small-cell carcinoma was more likely to present as distant disease and was associated with worse survival outcomes compared with squamous cell carcinoma, according to new research.

This video reviews ongoing trials testing immunotherapy for patients with head and neck cancer.

In this video we discuss efforts to reduce treatment doses in order to lessen long-term side effects and improve quality of life among patients with head and neck cancers.

Head and neck cancer patients who have a human papillomavirus (HPV) infection detectable with a blood-based biomarker have a better prognosis compared with HPV-negative patients.

The US Food and Drug Administration (FDA) in record time has approved nivolumab (Opdivo) for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after a platinum-based therapy.

A study presented last month at ASTRO found that better radiation outcomes for head and neck cancer were associated with higher facility volume.

Chronic sinusitis is associated with three rare types of head and neck cancer, including nasopharyngeal cancer, HPV-related oropharyngeal cancer, and nasal cavity and paranasal sinus cancers.

A 45-year-old man presents with a mass in the right neck. After the biopsy is performed, what is your diagnosis?

Clinicians now have a new treatment option for patients with recurrent or metastatic head and neck squamous cell carcinoma.

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses the recent priority review of nivolumab for use in metastatic head and neck cancer.

In this interview we discuss a joint statement from MD Anderson and 68 other NCI-designated cancer centers that calls for increased HPV vaccination for the prevention of cancer.

In this interview, Theodoros Teknos, MD, discusses the results of his current phase I trial of vorinostat (Zolinza) in advanced head and neck cancer.

To date, there is still no strong evidence that induction chemotherapy improves outcomes for locally advanced head and neck cancer.

Selumetinib has received Orphan Drug Designation status by the US Food and Drug Administration to be used as an adjuvant treatment in patients with stage III or IV differentiated thyroid cancer.